Drugs Acting on the Calcium Receptor. Calcimimetics and Calcilytics.

Principles of Bone Biology, Two-Volume Set

Volumn 2, Issue , 2008, Pages 1711-1735

  Nemeth, Edward F ^a  

^a NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882548082     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373884-4.00084-7     Document Type: Chapter

References (168)

1. Apostolou T., Damianou L., Kotsiev V., Dracopoulos S., Hadjiconstantinou V. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with calcimimetic agent cinacalcet. Clin. Nephrol. 2006, 65:374-377.
2. Apostolou T., Kollia K., Damianou L., Kaitsioti S., Dracopoulos S., Vougas V., Hadjiconstantinou V. Hypercalcemia due to resistant hyperparathyroidism in renal Ttansplant patients treated with the calcimimetic agent cinacalcet. Trans. Proc. 2006, 38:3514-3516.
3. Arey B.J., Seethala R., Ma Z., Fura A., Morin J., Swartz J., Vyas V., Yang W., Dickson J.K., Feyen J.H.M. A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. Endocrinology 2005, 146:2015-2022.
4. Ba J., Friedman P.A. Calcium-sensing receptor regulation of renal mineral ion transport. Cell Calcium 2004, 35:229-237.
5. Bai M. Structure and function of the extracellular calcium-sensing receptor. Int. J. Mol. Med. 1999, 4:115-125.
6. Bilezikian J.P., Potts J.T., El-Hajj Fuleihan G., Kleerekoper M., Neer R., Peacock M., Rastad J., Silverberg S.J., Udelsman R., Wells S.A. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J. Bone Miner. Res. 2002, 17:N2-nN11.
7. Block G.A., Cunningham J. Morbidity and mortality associated with abnormalities in bone and mineral metabolism in CKD. Clinical Guide to the Basics of Bone and Mineral Metabolism in CKD 2006, 77-92. National Kidney Foundation, New York. K. Olgaard (Ed.).
8. Block G.A., Preston S.K., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 2004, 15:2208-2218.
9. Block G.A., Martin K.J., de Francisco A.L.M., Turner S.A., Avram M.M., Suranyi M.G., Hercz G., Cunningham J., Abu-Alfa A.K., Messa P., Coyne D.W., Locatelli F., Cohen R.M., Evenepoel P., Moe S.M., Fournier A., Braun J., McCary L.C., Zani V.J., Olson K.A., Drüeke T.B., Goodman W.G. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 2004, 350(15):1516-1567.
10. Brauner-Osborne H., Jensen A.A., Sheppard P.O., O'Hara P., Krosgaard-Larsen P. The agonist-binding domain of the calcium-sensing receptor is located at the amino-terminal domain. J. Biol. Chem. 1999, 274:18382-18386.
11. Brown A.J., Slatopolsky E. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat. Clin. Prac. Endocrinol. Metab. 2007, 3:134-144.
12. Brown A.J., Ritter C.S., Finch J.L., Slatopolsky E.A. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int. 1999, 55:1284-1292.
13. Brown E.M. Clinical lessons from the calcium-sensing receptor. Nat. Clin. Prac. Endocrinol. Metab. 2007, 3:122-133.
14. Brown E.M., MacLeod R.J. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 2001, 81:239-297.
15. Bushinsky D.A., LaPlante K., Asplin J.R. Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats. Kidney Int. 2006, 69:1586-1592.
16. Cañadillas S., Canalejo A., Santamaría R., Rodríguez M.E., Estepa J.C., Martín-Malo A., Bravo J., Ramos B., Aguilera-Tejero E., Rodríguez M., Almadén Y. Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans. J. Am. Soc. Nephrol. 2005, 16:2190-2197.
17. 2+ set-point in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2000, 85:4789-4794.
18. Charytan C., Coburn J.W., Choncholm M., Herman J., Lien Y.H., Liu W., Klassen P.S., McCary L.C., Pichette V. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am. J. Kidney Dis. 2005, 46(1):58-67.
19. Chin J., Miller S.C., Michihito W., Nagano N., Nemeth E.F., Fox J. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J. Am. Soc. Nephrol. 2000, 11:903-911.
20. Clark O.H. Surgical treatment of primary hyperparathyroidism. Adv. Endocrinol. Metab. 1995, 6:1-16.
21. Coburn J.W., Salusky I.B. Hyperparathyroidism in renal failure. Clinical features, diagnosis, and management. The Parathyroids 1994, 519-529. Raven Press, Ltd., New York, NY. J.P. Bilezikian, M.A. Levine, R. Marcus (Eds.).
22. Collins M.T., Skarulis M.C., Bilezikian J.P., Silverberg S.J., Spiegel A.M., Marx S.J. Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J. Clin. Endocrinol. Metab. 1998, 83:1083-1088.
23. Colloton M., Shatzen E., Miller G., Stehman-Breen C., Wada M., Lacey D., Martin D. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005, 67:467-476.
24. Conigrave A.D., Brown E.M. Taste receptors in the gastrointestinal tract II. L-amino acid sensing by calcium-sensing receptors: Implications for GI physiology. Am. J. Physiol. 2006, 291:753-761.
25. Conigrave A.D., Hampson D.R. Broad-spectrum L-amino acid sensing by class 3 G-protein-coupled receptors. Trends. Endocrinol. Metab 2006, 17:398-407.
26. Conigrave A.D., Mun H.C., Delbridge L., Quinn S.J., Wilkinson M., Brown E.M. L-amino acids regulate parathyroid hormone secretion. J. Biol. Chem. 2004, 279:38151-38159.
27. Craver L., Marco M.P., Martinez I., Rue M., Borràs M., Martin M.L., Sarró F., Valdivielso J.M., Fernández E. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol. Dial. Trans. 2007, 22:1171-1176.
28. Cunningham J. Achieving therapeutic targets in the treatment of secondary hyperparathyroidism. Nephrol. Dial. Trans. 2004, 19(Supp. 5):v9-vv14.
29. Cunningham J., Danese M., Olson K., Klassen P., Chertow G.M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005, 68:1793-1800.
30. D'Amour P. Circulating PTH molecular forms: What we know and what we don't. Kidney Int 2006, 70:S29-sS33.
31. 2-(1-aryl)ethyl-3-phenylpropane-1 ,2-diamines as novel calcimimetics acting on the calcium sensing receptor. Bioorg. Med. Chem. Lett. 2000, 10:2001-2004.
32. Dempster D.W., Cosman F., Parisien M., Shen V., Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr. Rev. 1993, 14:690-709.
33. Denda M., Finch J., Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am. J. Kidney Dis. 1996, 28:596-602.
34. Dorsch O. Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism. Nephrol. Dial. Trans. 2007, 22:637-640.
35. Drüeke T.B. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int. 1995, 48:259-272.
36. El-Amm J., Doshi M.D., Singh A., Migdel S., Morawski K., Sternbauer D., Cincotta E., West M.S., Losanoff J.E., Gruber S.A. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007, 38:546-549.
37. Fajtova V.T., Quinn S.J., Brown E.M. Cytosolic calcium responses of single rMTC 44-2 cells to stimulation with external calcium and potassium. Am. J. Physiol 1991, 261:E151-eE158.
38. Fajtova V.T., Sayegh M.H., Hickey N., Aliabadi P., Lazarus J.M., LeBoff M.S. Intact parathyroid hormone levels in renal insufficiency. Calcif. Tissue Int. 1995, 57:329-335.
39. Farnebo F., Enberg U., Grimelius L., Backdahl M., Schalling M., Larsson C., Farnebo L.O. Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1997, 82:3481-3486.
40. Fischer J.A. "Asymptomatic" and symptomatic primary hyperparathyroidism. Clin. Invest. 1993, 71:505-518.
41. Fox J. Developments in parathyroid hormone and related peptides as bone-formation agents. Curr. Opin. Pharmacol. 2002, 2:338-344.
42. Fox J., Lowe S.H., Petty B.A., Nemeth E.F. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium. J. Pharmacol. Exp. Ther. 1999, 290:473-479.
43. Fox J., Lowe S.H., Conklin R.L., Petty B.A., Nemeth E.F. Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats. J. Pharmacol. Exp. Ther. 1999, 290:480-486.
44. Fox J., Lowe S.H., Conklin R.L., Nemeth E.F. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism. Endocrinology 1999, 10:97-103.
45. Fox J., Conklin R.L., Lambert L.D., Nemeth E.F. The potency of the calcimimetic NPS R-568 is unaffected in rats with severe secondary hyperparathyroidism. J. Am. Soc. Nephrol 2000, 11:575A.
46. Gal-Moscovici A., Sprague S.M. The role of calcimimetics in chronic kidney disease. Kidney Int. 2006, 70:S68-sS72.
47. Garrett J.E., Capuano I.V., Hammerland L.G., Hung B.C.P., Brown E.M., Hebert S.C., Nemeth E.F., Fuller F. Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J. Biol. Chem. 1995, 270:12919-12925.
48. Garrett J.E., Tamir H., Kifor O., Simin R.T., Rogers K.V., Mithal A., Gagel R.F., Brown E.M. Calcitonin-secreting cells of the thyroid express an extracellular calcium receptor gene. Endocrinology 1995, 136:5202-5211.
49. Garrett J.E., Steffey M.E., Nemeth E.F. The calcium receptor agonist NPS R-568 suppresses PTH mRNA levels in cultured bovine parathyroid cells. J. Bone Miner. Res. 1995, 10(Suppl 1):S387.
50. Gogusev J., Duchambon P., Hory B., Giovannini M., Goureau Y., Sarfati E., Drüeke T.B. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997, 51:328-336.
51. Goodman W.G. Calcimimetic agents for the treatment of secondary hyperparathyroidism. Semin. Nephrol. 2004, 24:460-463.
52. Goodman W.G. Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2005, 14:355-360.
53. Goodman W.G. Perspectives on renal bone disease. Kidney Int. 2006, 70:S59-sS63.
54. Goodman W.G., Hladik G.A., Turner S.A., Blaisdell P.W., Goodkin D.A., Liu W., Barri Y.M., Cohen R.M., Coburn J.W. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. 2002, 13:1017-1024.
55. Gowen M., Stroup G.B., Dodds R.A., James I.E., Votta B.J., Smith B.R., Bhatnagar P.K., Lago A.M., Callahan J.F., DelMar E.G., Miller M.A., Nemeth E.F., Fox J. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J. Clin. Invest. 2000, 105:1595-1604.
56. Gregoor P.S., de Jong G.M.T. Lithium hypercalcemia, hyperparathyroidism, and cinacalcet. Kidney Int. 2007, 71:470.
57. 2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol. Pharmacol. 1998, 53:1083-1088.
58. 2+ receptors. Mol. Pharmacol. 1999, 55:642-648.
59. 2+ receptor/metabotropic glutamate chimeric receptors. Endocrinology 2000, 141:4156-4163.
60. Harris R.Z., Padhi D., Marbury T.C., Noveck R.J., Salfi M., Sullivan J.T. Pharmacokinetics, pharmacodynamics, and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200mg once daily. Am. J. Kidney Dis. 2004, 44:1070-1076.
61. Harris R.Z., Salfi M., Posvar E., Hoelscher D., Padhi D. Pharmacokinetics of desipramine HCl when administered with HCl. Eur. J. Clin. Pharmacol. 2006, 63:159-163.
62. 2+ receptor/metabotropic glutamate chimeric receptors. Endocinology 2000, 141:4156-4163.
63. Heath H. Primary hyperparathyroidism: Recent advances in pathogenesis, diagnosis, and management. Adv. Intern. Med. 1991, 37:275-293.
64. 2+-sensing receptor in the gastrointestinal tract. Cell Calcium 2004, 35:239-247.
65. ®) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol. Dial. Trans. 2005, 20:1370-1377.
66. 2+-sensing receptor gene in human parathyroid tumors. J. Clin. Endocrinol. Metab. 1995, 80:3107-3110.
67. 2+ receptor converts a negative allosteric modulator into a positive allosteric modulator. J. Biol. Chem. 2006, 281:21558-21565.
68. Ishii H., Wada M., Furuya Y., Nagano N., Nemeth E.F., Fox J. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 2000, 26:175-182.
69. 2+-sensing receptor expression in parathyroid adenoma. Calcif. Tissue Int. 1999, 64:271-272.
70. Kawata T., Imanishi Y., Kobayashi K., Onoda N., Okuno S., Takemoto Y., Komo T., Tahara H., Wada M., Nagano N., Ishimura E., Miki T., Ishikawa T., Inaba M., Nishizawa Y. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J. Bone Miner. Metab. 2006, 24:300-306.
71. Kenakin T. New concepts in drug discovery: Collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 2005, 4:919-927.
72. 1-(1-(1-naphthyl)ethyl)-3-phenylpropanc e-1,2-diamines and conformationally restrained indole analogues: Development of calindol as a new calcimimetic acting at the calcium sensing receptor. Bioorg. Med. Chem. Lett. 2004, 14:3345-3349.
73. 2-(1-(1-naphthyl)ethyl)-1,2-diami nocylcohexanes: A new class of calcilytic agents acting at the calcium-sensing receptor. ChemBioChem 2004, 5:1131-1136.
74. 2-[1-(1-naphthyl)ethyl]-trans-1,2-diam inocyclohexanes: Development of 4-chlorophenylcarboxamide (Calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity. J. Med. Chem. 2006, 49:5119-5128.
75. Ketteler M., Gross M.L., Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int. 2005, 94(Suppl.):S120-sS127.
76. 2+ sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1996, 81:1598-1606.
77. Kruse A.E., Eisenberger U., Frey F.J., Mohaupt M.G. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol. Dial. Trans. 2005, 20:1311-1314.
78. Kumar G.N., Sproul C., Poppe L., Turner S., Gohdes M., Ghoborah H., Padhi D., Roskos L. Metabolism and disposition of calcimimetic agent cincalcet HCl in humans and animal models. Drug Metab. Disp. 2004, 32:1491-1500.
79. Lavigne J.R., Zahradnik R.J., Conklin R.L., Lambert L.D., Logan M.A., Parihar A., Fox J. Stimulation of calcitonin secretion by calcium receptor activators. Endocrinology 1998, 9:293-301.
80. Leca N., Laftavi M., Gundroo A., Kohli R., Min I., Karam J., Sridhar N., Blessios G., Venuto R., Pankewycz O. Early and severe hyperparathyroidism associated with hypercalemia after renal transplant treated with cinacalcet. Am. J. Transplant. 2006, 6:2391-2395.
81. Levi R., Ben-Dov I.Z., Lavi-Moshayoff V., Dinur M., Martin D., Naveh-Many T., Silver J. Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: Correlation with porttranslational modification of the trans acting factor. J. Am. Soc. Nephrol. 2006, 17:107-112.
82. Lewin E., Olgaard K. Parathyroidectomy vs calcimimetics for treatment of persistent hyperparathyroidism after kidney transplantation. Nephrol. Dial. Transplant. 2006, 21:1766-1769.
83. Lien Y-H.H., Silva A.L., Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 2005, 20:1232-1237.
84. Lindberg J.S., Moe S.M., Goodman W.G., Coburn J.W., Sprague S.M., Liu W., Blaisdell P.W., Brenner R.M., Turner S.A., Martin K.J. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003, 63:248-254.
85. Lindberg J.S., Culleton B., Wong G., Borah M.F., Clark R.V., Shapiro W.B., Roger S.D., Husserl F.E., Klassen P.S., Guo M.D., Albizem M.B., Coburn J.W. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J. Am. Soc. Nephrol. 2005, 16:800-807.
86. London G.M., Marchais S.J., Guerin A.P., Metivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr. Opin. Nephrol. Hypertens. 2005, 14:525-531.
87. Lopez I., Aguilera-Tejero A., Mendoza F.J., Almaden Y., Perez J., Martin D., Rodriguez M. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J. Am. Soc. Nephrol. 2006, 17:795-804.
88. Malluche H.H., Monier-Faugere M.C., Wang G., Frazao J.M., Charytan C., Coburn J.W., Coyne D.W., Kaplan M.R., Baker N., McCary L.C., Turner S.A., Goodman W.G. Cinacalcet HCl reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT). Abstracts XLI Congress Eur. Renal Assoc./Eur. Dial. Trans. Assoc. 2004, pp:218-219.
89. Martin K.J., González E.A. Metabolic bone disease in chronic kidney disease. J. Am. Soc. Nephrol. 2007, 18:875-885.
90. Martin K.J., Jüppner H., Sherrard D.J., Goodman W.G., Kaplan M.R., Nassar G., Campbell P., Curzi M., Charytan C., McCary L.C., Guo M.D., Turner S.A., Bashinsky D.A. First-and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int. 2005, 68:1236-1243.
91. Mathias R.S., Nguyen H.T., Zhang M.Y.H., Portale A.A. Reduced expression of the renal calcium-sensing receptor in rats with experimental chronic renal insufficiency. J. Am. Soc. Nephrol. 1998, 9:2067-2074.
92. Melamed M.L., Eustace J.A., Plantinga L., Jaar B.G., Fink N.E., Coresh J., Klag M.J., Powe N.R. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int. 2006, 70:351-357.
93. Miedlich S.U., Gama L., Seuwen K., Wolf R.M., Breitwieser G.E. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 2004, 279:7254-7263.
94. 2+-sensing receptor messenger ribonucleic acid and protein. Endocrinology 1995, 136:3087-3092.
95. Mizobuchi M., Hatamura I., Ogata H., Saji F., Uda S., Shizaki K., Sakaguchi T., Negi S., Kinugasa E., Koshikawa S., Akizawa T. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J. Am. Soc. Nephrol. 2004, 15:2579-2587.
96. Moe S.M., Drüeke T.B. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am. J. Nephrol. 2003, 23:369-379.
97. Moe S.M., Cunningham J., Bommer J., Adler S., Rosansky S.J., Urena-Torres P., Albizem M.B., Guo M.D., Zani V.J., Goodman W.G., Sprague S.M. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol. Dial. Transplant. 2005, 20:2186-2193.
98. Moe S.M., Chertow G.M., Coburn J.W., Quarles L.D., Goodman W.G., Block G.A., Drüeke T.B., Cunningham J., Sherrard D.J., McCary L.C., Olson K.A., Turner S.A., Martin K.J. Achieving NKF-K/DOQI TM bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005, 67:760-771.
99. Moe S., Drüeke T., Cunningham J., Goodman W., Martin K., Olgaard K., Ott S., Sprague S., Lameire N., Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006, 69:1945-1953.
100. 2+-sensing receptor Is required for L-Amino acid sensing. J. Biol. Chem. 2004, 279:51739-51744.
101. Nagano N. Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics): effect on the set point of calcium-regulated PTH secretion. Clin. Calcium 2005, 15:71-78.
102. Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol. Ther. 2006, 109:339-365.
103. Naveh-Many T., Silver J. Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J. Clin. Invest. 1990, 86:1313-1319.
104. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 2003, 42(Suppl. 4):S1-sS201. NKF-K/DOQI™.
105. Nordenstrom E., Westerdahl J., Bergenfelz A. Recovery of bone mineral density in 126 patients after surgery for primary hyperparathyroidism. World J. Surg. 2004, 28:502-507.
106. Nemeth E.F. Regulation of cytosolic calcium by extracellular divalent cations in C-cells and parathyroid cells. Cell Calcium 1990, 11:323-327.
107. Nemeth E.F. Calcium receptors as novel drug targets. Principles of Bone Biology 1996, 1339-1359. New York, NY, Academic Press. J.P. Bilezikian, L.G. Raisz, G.A. Rodan (Eds.).
108. Nemeth E.F. Calcium receptors as novel drug targets. Principles of Bone Biology 2002, 1339-1359. Academic Press, New York, NY. 2nd Ed. J.P. Bilezikian, L.G. Raisz, G.A. Rodan (Eds.).
109. Nemeth E.F. Pharmacological regulation of parathyroid hormone secretion. Curr. Pharmaceut. Des. 2002, 8:2077-2087.
110. Nemeth E.F. The search for calcium receptor antagonists (calcilytics). J. Mol. Endocrinol. 2002, 29:15-21.
111. Nemeth E.F., Bennett S.A. Tricking the parathyroid gland with novel calcimimetic agents. Nephrol. Dial. Transplant. 1998, 13:1923-1925.
112. Nemeth E.F., Fox J. Calcimimetic compounds: A direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol. Metab. 1999, 10:66-71.
113. Nemeth E.F., Steffey M.E., Hammerland L., Hung B.C.P., Van Wagenen B.C., DelMar E.G., Balandrin M.F. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. USA, 1998, 95:4040-4045.
114. 2+ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther. 2001, 299:323-331.
115. Nemeth E.F., Heaton W.H., Miller M., Fox J., Balandrin M.F., Van Wagenen B.C., Colloton M., Karbon W., Scherrer J., Shatzen E., Rishton G., Scully S., Qi M., Harris R., Lacey D., Martin D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 2004, 308:627-635.
116. Ogata H., Ritz E., Odoni G., Amann K., Orth S.R. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J. Am. Soc. Nephrol. 2003, 14:959-967.
117. ®). Clin. Pharmacokinet. 2005, 44:509-516.
118. Pattaragarn A., Fox J., Alon U.S. Effect of the calcimimetic NPS R-467 on furosemide-induced nephrocalcinosis in the young rat. Kidney Int. 2004, 65:1684-1689.
119. Peacock M., Bilezikian J.P., Klassen P.S., Guo M.D., Turner S.A., Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2005, 90(1):135-141.
120. 2+-sensing receptor. J. Biol. Chem. 2003, 278:49487-49494.
121. 2+-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. J. Biol. Chem. 2004, 279:18990-18997.
122. Quarles D.L., Sherrard D.J., Adler S., Rosansky S.J., McCary L.C., Liu W., Turner S.W., Bushinsky D.A. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J. Am. Soc. Nephrol 2003, 14:575-583.
123. Raue F., Scherübl H. Extracellular calcium sensitivity and voltage-dependent calcium channels in C cells. Endocrin. Rev. 1995, 16:752-764.
124. 2+ receptor. J. Biol. Chem. 2002, 277:18908-18913.
125. Ray K., Clapp P., Goldsmith P.K., Spiegel A.M. Identification of the sites of N-linked glycosylation on the human calcium receptor and assessment of their role in cell surface expression and signal transduction. J. Biol. Chem. 1998, 273:34558-34567.
126. 2+. J. Biol. Chem. 2005, 280:37013-37020.
127. Reichel H. Current treatment options in secondary renal hyperparathyroidism. Nephrol. Dial. Transplant. 2006, 21:23-28.
128. Ridefelt P., Liu Y.-J., Rastad J., Akerstroaum G., Gylfe E. Calcium sensing by human medullary thyroid carcinoma cells. FEBS Lett. 1994, 337:243-247.
129. Rittmaster R.S., Bolognese M., Ettinger M.P., Hanley D.A., Hodsman A.B., Kendler D.L., Rosen C.J. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab. 2000, 85:2129-2134.
130. Ritz E., Gross M-L., Dikow R. Role of calcium-phosphorus disorders in the progression of renal failure. Kidney Int. 2005, 68(Suppl. 99):S66-sS70.
131. Robinson M.R., Augustine J.J., Korman N.J. Cinacalcet for the treatment of calciphylaxis. Arch. Dermatol. 2007, 143:152-154.
132. Rodriguez M., Nemeth E., Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am. J. Physiol. 2005, 288:F253-fF264.
133. Rubin M.R., Sliney J., Silverberg S.J., Bilezikian J.P. Clinical course of 10 patients with inoperable parathyroid carcinoma treated with the calcimimetic cinacalcet HCl. J. Bone Miner. Metab. 2004, 19(Suppl. 1):S103.
134. Schmitt C.P., Hessing S., Oh J., Weber L., Ochlich P., Mehls O. Intermittent administration of parathyroid hormone (1-37) improves growth and bone mineral density in uremic rats. Kidney Int. 2000, 57:1484-1492.
135. Schmitt C.P., Odenwald T., Ritz E. Calcium, calcium regulatory hormones, and calcimimetics: Impact on cardiovascular mortality. J. Am. Soc. Nephrol. 2006, 17:S78-sS80.
136. Schwarz S., Trivedi B.K., Kalantar-Zadeh K., Kovesdy C.P. Association of disorders of mineral metabolism with progression of chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2006, 1:825-831.
137. Serra A.L., Schwarz A.A., Wick F.H., Marti H., Wüthrich R.P. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol. Dial. Transplant. 2005, 20:1315-1319.
138. Shane E., Bilezikian J.P. Parathyroid carcinoma: a review of 62 patients. Endocr. Rev. 1982, 3:218-226.
139. 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg. Med. Chem. Lett. 2005, 15:1557-1560.
140. Shcherbakova I., Huang G., Geoffroy O.J., Nair S.K., Swierczek K., Balandrin M.F., Fox J., Heaton W.L., Conklin R.L. Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg. Med. Chem. Lett. 2005, 15:2537-2540.
141. Shoback D.M., Bilezikian J.P., Turner S.A., McCary L.C., Guo M.D., Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 2003, 88(12):5644-5649.
142. 2+ binding pocket within the venus flytrap module of the human calcium-sensing receptor. J. Biol. Chem. 2005, 280:37917-37923.
143. Silverberg S.J., Gartenberg F., Jacobs T.P., Shane E., Siris E., Staron R.B., McMahon D.J., Bilezekian J.P. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1995, 80:729-734.
144. Silverberg S.J., Bone H.G., Marriott T.B., Locker F.G., Thys-Jacobs S., Dziem G., Kaatz S., Sanguinetti E.L., Bilezikian J.P. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N. Engl. J. Med. 1997, 337:1506-1510.
145. Silverberg S.J., Faiman C., Bilezikian J.P., Shoback D.M., Rubin M.R., Smallridge R., Schwanauer L.E., Olson K.A., Turner S.A., Peacock M. Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma. J. Bone Miner. Metab. 2004, 19(Suppl. 1):S103.
146. Spiegel D.M., Casey L., Bell S., Parker M., Chonchol M. Achieving targets for bone and mineral metabolism; the impact of cinacalcet HCl in clinical practice. Hemodial. Int. 2006, 10:S24-sS27.
147. Srinivas T.R., Schold J.D., Womer K.L., Kaplan B., Howard R.J., Bucci C.M., Meier-Kriesche H-U. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin. J. Am. Soc. Nephrol. 2006, 1:323.
148. Stevens L.A., Djurdjev O., Cardew S., Cameron E.C., Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J. Am. Soc. Nephrol. 2004, 15:770-779.
149. Strippoli G.F.M., Palmer S., Tong A., Elder G., Messa P., Craig J.C. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am. J. Kidney Dis. 2006, 47:715-726.
150. Szczech L.A. The impact of calcimimetic agents on the use of different classes of phosphate binders: results of recent clinical trials. Kidney Int. 2004, 66(Suppl. 90):S46-sS48.
151. Szwarc I., Argiles A., Garrigue V., Delmas S., Chong G., Deleuze S., Mourad G. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006, 82:675.
152. Tanaguchi M., Tokumoto M., Matsuo D., Sugitani A., Kuroki S., Yotsueda H., Tsuruya K., Hirakata H., Iida M. Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006, 70:363-370.
153. Tanaguchi M., Tokumoto M., Matsuo D., Tsuruya K., Hirakata H., Iida M. Parathyroid growth and regression in experimental uremia. Kidney Int. 2006, 69:464-470.
154. Torres P.U. Clinical experience with cinacalcet HCl. Nephrol. Dial. Transplant. 2004, 19(Suppl.5):v27-vv33.
155. Torres P.U., Prié D., Beck L., Friedlander G. New therapies for uremic secondary hyperparathyroidism. J. Renal Nutr. 2006, 16:87-99.
156. Velasco N., MacGregor M.S., Innes A., MacKay I.G. Successful treatment of calciphylaxis with cinacalcet-an alternative to perathyroidectomy. Nephrol. Dial. Transplant. 2006, 21:1999-2004.
157. Vestergaard P. Current pharmacological options for the management of primary hyperparathyroidism. Drugs 2006, 66(17):2189-2211.
158. Wada M., Nagano N. Control of parathyroid cell growth by calcimimetics. Nephrol. Dial. Transplant 2003, 18(Suppl. 3):iii13-iiiiii17.
159. Wada M., Furuya Y., Sakiyama J., Kobayashi N., Miyata S., Ishii H., Nagano N. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: Control of parathyroid cell growth via a calcium receptor. J. Clin. Invest. 1997, 100:2977-2983.
160. Wada M., Ishii H., Furuya Y., Fox J., Nemeth E.F., Nagano N. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int. 1998, 53:448-453.
161. Wada M., Nagano N., Furuya Y., Chin J., Nemeth E.F., Fox J. Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int. 2000, 57:50-58.
162. Wada M., Furuya Y., Kobayashi N., Miyata S., Ishii H., Nagano N. The calcimimetic compound AMG 073 (cinacalcet HCl) ameliorates osteitis fibrosa in rats with chronic renal insufficiency. J. Am. Soc. Nephrol. 2003, 14:48A.
163. Wang M., Yao Y., Kuang D., Hampson D.R. Activation of family C G-protein-coupled receptors by the tripeptide glutathione. J. Biol. Chem. 2006, 281:8864-8870.
164. Wilmer W.A., Magro C.M. Calciphylaxis: Emerging concepts in prevention, diagnosis, and treatment. Semin. Dial. 2002, 15:172-186.
165. Wood C., Gonzalez E.A., Martin K.J. Challenges in the therapy of secondary hyperparathyroidism. Ther. Apheresis Dial. 2005, 9:4-8.
166. Yang W., Wang Y., Roberge J.Y., Ma Z., Liu Y., Lawrence R.M., Rotella D.P., Seethala R., Feyen J.H.M., Dickson J.K. Discovery and structure-activity relationships of 2-benzylpyrrolidine-substituted aryloxypropanols as calcium-sensing receptor antagonists. Bioorg. Med. Chem. Lett. 2005, 15:1225-1228.
167. Zhang Z., Jiang Y., Quinn S.J., Krapcho K., Nemeth E.F., Bai M. L-Phenylalanine and NPS R-467 synergistically potentiate the function of the extracellular calcium-sensing receptor through distinct sites. J. Biol. Chem. 2002, 277:33736-33741.
168. Zhu B.T. The competitive and noncompetitive antagonism of receptor-medicated drug actions in the presence of spare receptors. J. Pharmacol. Exp. Ther. 1993, 29:85-91.